Drug Trial News

RSS

Seattle Genetics commences everolimus-SGN-75 combination phase Ib clinical trial for advanced RCC

Seattle Genetics, Inc. today announced the initiation of a phase Ib clinical trial evaluating SGN-75 in combination with everolimus (Afinitor) for patients with advanced metastatic renal cell carcinoma (RCC).

24 Aug 2012

Lilly’s solanezumab Phase 3 trials on AD do not meet primary endpoints

Eli Lilly and Company today announced that the primary endpoints, both cognitive and functional, were not met in either of the two Phase 3, double-blind, placebo-controlled solanezumab EXPEDITION trials in patients with mild-to-moderate Alzheimer's disease.

24 Aug 2012

Dartmouth’s professor shares news of DAR-901 TB vaccine development

Tuberculosis (TB) is second only to HIV/AIDS as the greatest killer worldwide attributable to a single infectious agent, according to the World Health Organization (WHO). With 8.8 million cases in 2010 and 95 percent of TB deaths occurring in low- and middle-income countries, the disease continues to be a major public health problem in the developing world. In a July address to the International Union Against Tuberculosis and Lung Disease, Dartmouth's C. Fordham (Ford) von Reyn shared news of a promising vaccine in the works.

24 Aug 2012

Pre-emptive therapy better than valacyclovir prophylaxis in treating CMV in transplant recipients

Waiting to treat the commonest viral infections in transplant recipients until they reach a certain threshold is better than prophylactically treating all recipients, according to a study appearing in an upcoming issue of the Journal of the American Society of Nephrology (JASN).

24 Aug 2012

Diabetes journal reports results from novel experimental therapy

Results from a novel experimental therapy for Type 1 diabetes that boosts parts of the healthy immune system are reported today in the scientific journal Diabetes.

24 Aug 2012

Bristol-Myers Squibb terminates BMS-986094 Phase II development for treatment of hepatitis C

Bristol-Myers Squibb Company announced today that the Company has discontinued development of BMS-986094 (formerly known as INX-189), a nucleotide polymerase (NS5B) inhibitor that was in Phase II development for the treatment of hepatitis C.

24 Aug 2012

Results from Biodesix VeriStrat phase II advanced lung cancer trials

Biodesix today announced that VeriStrat results from two phase II advanced lung cancer trials will be presented at the upcoming 2012 Chicago Multidisciplinary Symposium in Thoracic Oncology.

24 Aug 2012

NW Bio receives MHRA approval to initiate DCVax-L Phase III GBM brain cancer trial in the U.K.

Northwest Biotherapeutics announced today that it has received approval from the Medicines and Healthcare Products Regulatory Agency (MHRA) of the United Kingdom, for the Company's 300-patient Phase III clinical trial of DCVax-L immune therapy for Glioblastoma multiforme brain cancer (GBM) to proceed in the U.K.

24 Aug 2012

AcelRx commences third ARX-01 Phase 3 study in post-operative pain

AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced dosing of the first patient in the third of three planned Phase 3 studies for ARX-01, the Sufentanil NanoTab PCA System, its novel sublingual patient-controlled analgesia (PCA) system.

24 Aug 2012

Aeras, IDRI announce start of first ID93 + GLA-SE Phase I trial for tuberculosis

Aeras and the Infectious Disease Research Institute (IDRI) announce today the start of the first clinical trial of IDRI's novel tuberculosis vaccine candidate, ID93 + GLA-SE.

23 Aug 2012

Final data from Symphogen's rozrolimupab Phase 2 trial on primary immune thrombocytopenia

The hematology journal BLOOD published today a full-length article describing final Phase 2 data for Symphogen's rozrolimupab, a novel human recombinant mixture of 25 antibodies which all are manufactured simultaneously from a single batch.

22 Aug 2012

CIRT to determine whether methotrexate can reduce heart attacks, strokes and CVD deaths

An international multi-site trial has launched to determine whether a common anti-inflammatory drug can reduce heart attacks, strokes, and deaths due to cardiovascular disease in people at high risk for them. This study is being supported by the National Heart, Lung, and Blood Institute (NHLBI), a part of the National Institutes of Health.

22 Aug 2012

PhaseBio commences Glymera Phase 2b study in type 2 diabetes

PhaseBio Pharmaceuticals, Inc., a privately held, clinical-stage biotechnology company developing drugs to treat diabetes, metabolic disease and cardiovascular disease, announced today that it has initiated dosing in a multicenter (USA), randomized, placebo and active comparator controlled Phase 2b study that will enroll approximately 600 patients with type 2 diabetes (hemoglobin A1c 7% - 11%) inadequately controlled with diet and exercise, metformin, a sulfonylurea or a combination of metformin/sulfonylurea.

22 Aug 2012

Kineta receives regulatory clearance to commence ShK-186 Phase I trial in autoimmune disease

Seattle-based biotech company Kineta, Inc. announced today it has received regulatory clearance in the Netherlands to initiate a first-in-human trial of ShK-186, an autoimmune drug candidate that specifically inhibits the Kv1.3 potassium ion channel.

21 Aug 2012

DPT Labs, Imprimis sign agreement to commence work on Impracor clinical supplies

Imprimis Pharmaceuticals, Inc., a specialty pharmaceutical company developing non-invasive, topically delivered products, announced that it has signed an agreement with DPT Labs to commence work on supplying Imprimis with quantities of its active topical anti-inflammatory drug, Impracor, for currently planned Phase 3 clinical trials.

21 Aug 2012

MitoTarget Project and neurodegenerative diseases: an interview with Rebecca Pruss, Ph.D., CSO of Trophos

The MitoTarget Project was a project funded by the European Commission, under their FP7 programme. It was funding for a call published in 2007.

21 Aug 2012

Medivir initiates MIV-711 phase Ib trial in healthy volunteers

Medivir AB, the research-based pharmaceutical company focused on the development of high-value treatments for infectious diseases, is reporting today that a clinical phase Ib trial of the company's candidate drug (CD) MIV-711 has commenced.

21 Aug 2012

Daily vitamin D intake protects against respiratory infections in children

A study conducted in Mongolian schoolchildren supports the possibility that daily vitamin D supplementation can reduce the risk of respiratory infections in winter. In a report that will appear in the journal Pediatrics and has received early online release, an international research team found that vitamin D supplementation decreased the risk of respiratory infections among children who had low blood levels of vitamin D at the start of the study.

21 Aug 2012

Encouraging results from Ocular Therapeutix's travoprost Phase II trial on glaucoma

Following encouraging results from Ocular Therapeutix's travoprost punctum plug feasibility study, the company is now entering a pilot Phase II clinical trial to examine a two-month sustained release drug (OTX-TP2) for the treatment of ocular hypertension and glaucoma.

21 Aug 2012

BioDiem and French partner VIVALIS a step forward in developing vaccines for diseases and related cancers

Australian infectious disease therapy and vaccine development company BioDiem Ltd (ASX: BDM) announced today successful results from two programs of work carried out by French partner VIVALIS (NYSE Euronext: VLS), confirming the ability of BioDiem’s Live Attenuated Influenza Virus (LAIV) to grow in VIVALIS’ proprietary EB66® cell line.

20 Aug 2012

Drug Trial News

Seattle Genetics commences everolimus-SGN-75 combination phase Ib clinical trial for advanced RCC

Lilly’s solanezumab Phase 3 trials on AD do not meet primary endpoints

Dartmouth’s professor shares news of DAR-901 TB vaccine development

Pre-emptive therapy better than valacyclovir prophylaxis in treating CMV in transplant recipients

Diabetes journal reports results from novel experimental therapy

Bristol-Myers Squibb terminates BMS-986094 Phase II development for treatment of hepatitis C

Results from Biodesix VeriStrat phase II advanced lung cancer trials

NW Bio receives MHRA approval to initiate DCVax-L Phase III GBM brain cancer trial in the U.K.

AcelRx commences third ARX-01 Phase 3 study in post-operative pain

Aeras, IDRI announce start of first ID93 + GLA-SE Phase I trial for tuberculosis

Final data from Symphogen's rozrolimupab Phase 2 trial on primary immune thrombocytopenia

CIRT to determine whether methotrexate can reduce heart attacks, strokes and CVD deaths

PhaseBio commences Glymera Phase 2b study in type 2 diabetes

Kineta receives regulatory clearance to commence ShK-186 Phase I trial in autoimmune disease

DPT Labs, Imprimis sign agreement to commence work on Impracor clinical supplies

MitoTarget Project and neurodegenerative diseases: an interview with Rebecca Pruss, Ph.D., CSO of Trophos

Medivir initiates MIV-711 phase Ib trial in healthy volunteers

Daily vitamin D intake protects against respiratory infections in children

Encouraging results from Ocular Therapeutix's travoprost Phase II trial on glaucoma

BioDiem and French partner VIVALIS a step forward in developing vaccines for diseases and related cancers

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Digital pathology and the PathoVerse: A conversation with Dr. Singh

Bioprocess Efficiency with Cell Density Monitoring

Latest News